Shift Pharmaceuticals Holdings, Inc.
Columbia, MO Doing business as Shift Pharmaceuticals Impedx Diagnostics
- UEI
- L5YJHR8PKA96
- CAGE
- 7TJM2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1601 S Providence Rd, Columbia, MO 65203, USA
- Website
- shiftpharmaceuticals.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating… | National Eye Institute | $312,239 | |
| IND enabling non-clinical development of E1V1.11, a morpholino anti-sense oligonucleotide for the treatment of spinal… | National Institute of Neurological Disorders and Stroke | $360,937 | |
| Development of novel ASO-based therapeutics for CMT1A - abstract: the objective of this project is to develop a safe,… | National Institute of Neurological Disorders and Stroke | $513,160 | |
| Multi-dose pre-clinical studies in RAT for E1-targeting antisense oligonucleotides | National Institute of Neurological Disorders and Stroke | $228,113 | |
| Development of a splice-switching antisense oligonucleotide for the treatment of spinal muscular atrophy | Medical Command | $6,048,654 |
About Shift Pharmaceuticals Holdings, Inc.
Shift Pharmaceuticals Holdings, Inc., registered in SAM.gov since May 16, 2019, is a for-profit corporate entity located in Columbia, Missouri, specializing in developing advanced antisense oligonucleotide (ASO) therapeutics targeting complex genetic and neurological disorders. The company focuses on innovative pharmaceutical research and development, with a particular emphasis on creating targeted molecular therapies that address genetic diseases through precise genetic intervention strategies. Through its Impedx Diagnostics Division, Shift Pharmaceuticals demonstrates a sophisticated approach to developing cutting-edge medical treatments that target specific genetic mechanisms underlying various challenging medical conditions.
The company has secured multiple federal grants from the National Institute of Neurological Disorders and Stroke and the National Eye Institute, focusing on developing specialized antisense oligonucleotide therapies for complex medical conditions. Specifically, Shift Pharmaceuticals has pursued grant-funded research in three key areas: developing an ASO therapeutic for Spinal Muscular Atrophy (SMA) with a lead candidate (E1V1.11) that shows significant improvements in animal model survival rates, creating targeted therapies for Charcot-Marie-Tooth disease type 1A (CMT1A) by modulating PMP22 protein production, and designing ASO inhibitors to mitigate vision loss in retinitis pigmentosa and age-related macular degeneration by targeting retinoic acid signaling. These research projects demonstrate the company's sophisticated approach to developing precision molecular therapies that can potentially address critical unmet medical needs through advanced genetic intervention strategies.
Quick answers
What is Shift Pharmaceuticals Holdings, Inc.'s UEI?
Shift Pharmaceuticals Holdings, Inc.'s Unique Entity ID (UEI) in SAM.gov is L5YJHR8PKA96.
What is Shift Pharmaceuticals Holdings, Inc.'s CAGE code?
Shift Pharmaceuticals Holdings, Inc.'s CAGE code is 7TJM2.
What is Shift Pharmaceuticals Holdings, Inc.'s primary NAICS code?
Shift Pharmaceuticals Holdings, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Shift Pharmaceuticals Holdings, Inc. located?
Shift Pharmaceuticals Holdings, Inc.'s physical address in SAM.gov is 1601 S Providence Rd, Columbia, MO 65203, USA.
Is Shift Pharmaceuticals Holdings, Inc. registered in SAM.gov?
Yes. Shift Pharmaceuticals Holdings, Inc.'s SAM.gov registration is active through August 31, 2027.
What is Shift Pharmaceuticals Holdings, Inc.'s most recent federal award?
Shift Pharmaceuticals Holdings, Inc.'s most recent federal grant award is Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating… (R41EY036319), from National Eye Institute, on August 1, 2025.
On GovTribe
See Shift Pharmaceuticals Holdings, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors